Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. Executive Chairman Michael H. Tardugno reported updated holdings of the company’s common stock. He received a grant of 4,410 shares of common stock at $1.91 per share, described as stock granted in lieu of cash for base salary, increasing his direct ownership to 64,396 shares. A separate line shows 4,622 shares held indirectly through an IRA, reflecting indirect ownership rather than a new market transaction.
Imunon, Inc. CFO Joshua Blacher files an initial ownership report on Form 3. This filing identifies Blacher as an officer of the company with the title of Chief Financial Officer. The data provided does not list any specific transactions or derivative positions, indicating this is a baseline disclosure of his status as a reporting person under SEC rules.
Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, reported two recent transactions in the company's common stock. On July 2, 2026, she acquired 920 shares at $1.91 per share as a stock grant in lieu of a portion of her base salary. On July 6, 2026, she executed an open-market sale of 920 shares at $1.88 per share. After these transactions, she directly holds 2,896 shares of Imunon common stock.
Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. reported that its Chief Medical Officer, Douglas Vincent Faller, received a stock grant of 1,308 shares of Common Stock on July 2, 2026 at a reference price of $1.91 per share. According to the footnote, this stock was granted in lieu of cash for a portion of his base salary, making it a compensation-related, non-market transaction rather than an open-market purchase. Following this award, Faller directly holds 23,204 shares of Imunon common stock.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. President and CEO Stacy Lindborg received an equity grant of 2,534 shares of common stock at $1.91 per share in lieu of a portion of base salary. After this compensation-related award, she holds 76,722 shares directly and 778 shares indirectly through a 401(k) plan.
Imunon, Inc. announced that interim Chief Financial Officer Jeffrey Church plans to retire from his role effective July 1, 2026. To support continuity, he will remain with the company as a consultant under an amended agreement with a $10,000 monthly retainer, cancellable on two business days’ notice.
Effective the same date, Imunon appointed Josh Blacher as its new interim Chief Financial Officer through a master services agreement with Danforth Health, Inc. Imunon will pay Danforth $475 per hour for his CFO services. The filing notes Mr. Church’s departure is due to retirement and not related to any disagreement with management, and confirms that Mr. Blacher has no disclosed related-party relationships or conflicts.
Imunon, Inc.’s Chief Medical Officer, Douglas Vincent Faller, received a stock-based bonus rather than a cash payment. He was granted 21,896 shares of Imunon common stock at a reference price of $1.72 per share as part of his 2025 compensation.
The footnote explains this stock grant was given in lieu of cash for 50% of his 2025 annual cash bonus. Following the grant, Faller directly owns 21,896 Imunon common shares, and the filing shows no related option exercises, sales, or derivative positions.
Imunon, Inc. General Counsel and Corporate Secretary Susan Eylward reported both an equity award and a stock sale. On June 25, 2026, she acquired 14,696 shares of common stock at $1.72 per share as a grant in lieu of cash for 50% of her 2025 annual cash bonus. On June 29, 2026, she executed an open-market sale of 11,800 shares at a weighted average price of $1.752 per share, with individual sale prices ranging from $1.73 to $1.80 per share. Following the sale, she directly owned 2,896 shares of Imunon common stock.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. Executive Chairman Michael H. Tardugno received a stock grant as part of his 2025 compensation. He was awarded 42,519 shares of common stock at $1.72 per share, granted in lieu of cash for 50% of his 2025 annual cash bonus.
Following this grant, Tardugno holds 59,986 shares of Imunon common stock directly, plus 4,622 shares held indirectly through an IRA. The filing shows a compensation-related share award rather than an open-market purchase or sale.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. President and CEO Stacy Lindborg reported a stock-based compensation grant on Common Stock. She was awarded 67,150 shares at $1.72 per share as stock granted in lieu of cash for 50% of her 2025 annual cash bonus. Following this grant, she directly holds 74,188 shares of Common Stock. She also has an indirect holding of 778 shares through a 401(k) plan, which reflects plan holdings rather than a new market transaction.